Pipeline Insight Lymphomas, Multiple Myeloma and Myelodysplastic Syndromes Optimization of clinical practice

The commercial success of Rituxan in theThere are currently 107 drugs in clinical
treatment of NHL and Velcade and Revlimid in thedevelopment for NHL, of which 12 are in late
treatment of MM has attracted the interest ofphase development. This high R&D activity is
pharmaceutical companies to these markets.due to the diverse nature of the diseases and the
There are 173 drugs in clinical development forsuccess of therapies such as Rituxan in these
these indications, the majority of which areindications. Targeted therapies account for over
molecular targeted therapies (MTTs). Thishalf of drugs in development for NHL.
contrasts with HL and MDS where there is limitedThere are currently 15 drugs in clinical
pipeline activity.development for HL, of which 3 are in late phase
Scopedevelopment. Unmet needs persists in HL but are
* Examination of key pipeline candidates withconfined to relapsed patients and elderly patients,
in-depth clinical and commercial profiles of Phasewhich are relatively small patient populations.
III candidatesThere are currently 66 drugs in clinical
* Seven major pharmaceutical market salesdevelopment for MM, of which 8 are in late phase
forecasts for Phase III pipeline products throughdevelopment. MM is an incurable disease and there
to 2019 with product-specific assumptionsis a need for better and less toxic therapies
Highlightsacross all lines of treatment.